To read the full story, subscribe or sign in.

Chipscreen’s PPAR pan-agonist Bilessglu wins NMPA nod for treatment of type 2 diabetes

Oct. 20, 2021

Shenzhen Chipscreen Biosciences Co. Ltd.’s Bilessglu (chiglitazar), a peroxisome proliferator-activated receptor (PPAR) pan-agonist globally for the treatment of type 2 diabetes mellitus, has received marketing approval from the NMPA in China.

BioWorld Regulatory Diabetes China NMPA

Today's news in brief

BioWorld

BioWorld briefs for July 15, 2025.

Circode applies circRNA to heart disease drug R&D, in vivo CAR T

BioWorld

Shanghai Circode Biomed Co. Ltd. is set to begin clinical trials of HM-2002, a circular RNA (circRNA)-based drug for ischemic heart disease, having gained IND...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 15, 2025.

Proteomics finds surprise commonalities as well as differences in neurodegenerative diseases

BioWorld

The switch will be flicked today to make the world’s largest dementia-related proteomics dataset freely available to researchers, at the same time as members of...

BD’s biosciences & diagnostics unit in $17.5B merger with Waters

BioWorld MedTech

Three months earlier than an expected update on a deal, Becton, Dickinson and Co. reported its biosciences and diagnostic solutions business will combine with...